Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

被引：0
作者：
Alice Mogenet
Pascal Finetti
Emilie Denicolai
Laurent Greillier
Pascaline Boudou-Rouquette
François Goldwasser
Gwenael Lumet
Michele Ceccarelli
Daniel Birnbaum
Davide Bedognetti
Emilie Mamessier
Fabrice Barlesi
François Bertucci
Pascale Tomasini
机构：
[1] Aix Marseille Univ,Multidisciplinary Oncology and Therapeutic Innovations Department
[2] APHM,Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d’Oncologie Prédictive
[3] INSERM,Department of Medical Oncology, Cochin Hospital, AP
[4] CNRS,HP, Paris
[5] CRCM,Sylvester Comprehensive Cancer Center, Department of Public Health Sciences
[6] Hôpital Nord,Division of Translational Medicine, Research Branch
[7] Aix Marseille Univ,Department of Internal Medicine and Medical Specialties
[8] France–University of Paris Descartes,Department of Medical Oncology, Institut Paoli
[9] ARIANE,Calmettes
[10] CARPEM,undefined
[11] University of Miami Miller School of Medicine,undefined
[12] Sidra Medicine,undefined
[13] University of Genoa,undefined
[14] Paris-Saclay University and Medical Oncology,undefined
[15] Gustave Roussy,undefined
[16] Aix Marseille Univ,undefined
来源：
Journal of Translational Medicine | / 21卷
关键词：
Lung cancer; ICR signature; Immune therapy; Biomarkers; Immune checkpoints inhibitors; Transcriptomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 322 条
[1]  
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2022)Targeted therapies for lung cancer patients with oncogenic driver molecular alterations J Clin Oncol 40 611-625
[3]  
Siegel RL(2015)The journey from discoveries in fundamental immunology to cancer immunotherapy Cancer Cell 27 439-449
[4]  
Laversanne M(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-1639
[5]  
Soerjomataram I(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N Engl J Med 375 1823-1833
[6]  
Jemal A(2018)Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer N Engl J Med 378 2078-2092
[7]  
Tan AC(2022)Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee J Thorac Oncol 17 1335-1354
[8]  
Tan DSW(2017)PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data Immunotherapy 9 499-506
[9]  
Miller JFAP(2015)Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 10 985-989
[10]  
Sadelain M(2018)The clinical utility of tumor mutational burden in non-small cell lung cancer Transl Lung Cancer Res 7 639-646
12345678910